肝素治疗纤溶酶原激活剂抑制物-1基因启动因子区-6754 G/4G基因型基因所致重复流产孕妇的疗效探讨

The study of heparin for recurrent pregnancy loss with plasminogen activator inhiitor-1 gene 4G/4G polymorphism treating

目的探讨肝素(heparin)治疗纤溶酶原激活剂抑制物-1基因启动因子区-6754G/4G基因型基因所致重复流产的疗效。方法将56例反复性妊娠丢失患者(排除感染、内分泌、子宫附件、免疫等导致流产的其它因素,由纤溶酶原激活剂抑制物-1基因启动因子区-6754G/4G基因型基因),就诊后一经诊断为妊娠即给分为两组,分别给予肝素治疗或不给予任何干预。观察两组的妊娠结局。结果肝素治疗24例中,22例足月产(91.66%)、2例早产35.9±1.6w(33～37.6)并产出活婴(11.11%)、活产率100%。比对照组50%(12/24),差异有显著性(P<0.01)。结论肝素对纤溶酶原激活剂抑制物-1基因启动因子区-6754G/4G基因型基因所致重复流产孕妇的治疗效果显著。

Objective ： To evaluate the heparin treats recurrent pregnancy loss with plasminogen activator inhiitor - 1 gene 4G/4G polymorphism. Methods ： 56 patients with the syndrome of recurrent pregnancy loss （ except for other factors of resulting recurrent pregnancy loss such as immune; infection; internal secretion and womb and appendixes but with plasminogen activator inhiitor - 1 gene 4G/ 4G polymorphism） were randomized to received heparin or nothing treating. We observed the pregnancy outcome before and after medication of two groups. Results： In the groups of heparin, 22cases of pregnancy resulted in mature births （91.66%）. 2 cases resulted in live births （ 11.11% ） at 35.9 ± 1.6w （ range 33 - 37. 7 ）, and Apgar scores were good to excellent. The rate of in live birth 100% was significantly higher than that of control group （50%） （ P 〉 0. 01 ）. Conclusion ： The treating effect of heparin for recurrent pregnancy loss with plasminogen activator inhiitor - 1 gene 4G/4G polymorphism is remarkable.